Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

the Clinical Trial of Gefitinib(Non - Small Cell Lung Cancer)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03264794
Recruitment Status : Not yet recruiting
First Posted : August 29, 2017
Last Update Posted : August 29, 2017
Sponsor:
Information provided by (Responsible Party):
Jiangsu Famous Medical Technology Co., Ltd.

Brief Summary:
  1. Gefitinib CTTQ production gefitinib and erlotinib sheet AstraZeneca imatinib sheet (trade name: Iressa ®) comparison, human pharmacokinetics and relative bioavailability of comparative studies which examine people in vivo pharmacokinetic behavior, provide the basis for clinical use.
  2. Evaluation CTTQ gefitinib imatinib sheet production efficacy and safety of Chinese patients with locally advanced or metastatic non-small cell lung cancer.

Condition or disease Intervention/treatment Phase
Non-small Cell Lung Cancer Drug: Gefitinib Tab (CTTQ),First medication;Gefitinib Tab (CTTQ),From the 8th day of trial Drug: Gefitinib tablets (Yi Ruisha),First medication Drug: Gefitinib Tab 250 MG(CTTQ),From the 8th day of trial. Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Evaluation of the Efficacy of Domestic Gefitinib Tablets in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients Using a Multicenter, Randomized, Positive Drug Gefitinib Pharmacodynamics and Pharmacodynamics
Estimated Study Start Date : August 2017
Estimated Primary Completion Date : December 2021
Estimated Study Completion Date : June 2022

Resource links provided by the National Library of Medicine

Drug Information available for: Gefitinib

Arm Intervention/treatment
Experimental: trial group
Gefitinib tablets (CTTQ),First medication.From the 8th day of the experiment, treated with Gefitinib Tab(CTTQ)
Drug: Gefitinib Tab (CTTQ),First medication;Gefitinib Tab (CTTQ),From the 8th day of trial
Gefitinib Tab (CTTQ),First medication,250mg;

Drug: Gefitinib Tab 250 MG(CTTQ),From the 8th day of trial.
From the 8th day of the experiment, two groups of subjects were treated with Gefitinib(CTTQ)

Active Comparator: control group
Gefitinib tablets (Yi Ruisha),First medication.From the 8th day of the experiment, treated with Gefitinib Tab(CTTQ)
Drug: Gefitinib tablets (Yi Ruisha),First medication
Gefitinib tablets (Yi Ruisha),First medication,250mg;

Drug: Gefitinib Tab 250 MG(CTTQ),From the 8th day of trial.
From the 8th day of the experiment, two groups of subjects were treated with Gefitinib(CTTQ)




Primary Outcome Measures :
  1. Gefitinib plasma concentration [ Time Frame: 0hour before administration and 1, 2, 3, 4, 5, 6, 7, 8,9,13,24,48,72,120,168 16 hour time points after administration ]
    After the use of gefitinib to reach the highest plasma concentration

  2. Tmax time [ Time Frame: 0hour before administration and 1, 2, 3, 4, 5, 6, 7, 8,9,13,24,48,72,120,168 16 hour time points after administration ]
    Taking the time required for the concentration of gefitinib to reach the peak

  3. AUC0-t [ Time Frame: 0hour before administration and 1, 2, 3, 4, 5, 6, 7, 8,9,13,24,48,72,120,168 16 hour time points after administration ]
    The area between the axis of the coordinate and the time drug concentration curve

  4. t 1/2 [ Time Frame: 0hour before administration and 1, 2, 3, 4, 5, 6, 7, 8,9,13,24,48,72,120,168 16 hour time points after administration ]
    The time required for gefitinib to decrease by half the highest concentration in plasma

  5. F [ Time Frame: 0hour before administration and 1, 2, 3, 4, 5, 6, 7, 8,9,13,24,48,72,120,168 16 hour time points after administration ]
    Gefitinib absorbs the relative amount of blood into the cycle



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients volunteered to participate in this study, signed informed consent;
  2. ≥18 years old; ECOG PS score: 0 ~ 1; expected survival period of more than 3 months;
  3. patients with locally advanced or metastatic non-small cell lung cancer diagnosed by histology or cytology, who can not receive radical surgery or radiotherapy; patients with measurable lesions(according to RECIST criteria);
  4. Detection of EGFR-positive exon 19 deletion or exon 21 (L858R) mutation was performed by providing a detectable specimen (tissue or cancerous pleural effusion) prior to enrollment;
  5. The main organ function within 7 days before treatment, meet the following criteria:

(1) blood routine examination criteria (14 days without blood transfusion): A) hemoglobin≥ 90g / L; B) neutrophil absolute ≥ 1.5 × 109 / L; C) platelet ≥80 × 109 / L (2) biochemical tests to meet the following criteria: A) total bilirubin ≤ 1.5 times the upper limit of normal (ULN); B) alanine aminotransferase and aspartate aminotransferase AST ≤ 2.5ULN, such as liver metastasis, ALT and AST ≤ 5ULN; C) serum creatinine ≤ 1.5ULN or creatinine clearance ≥ 60ml / min; (3) Doppler ultrasound evaluation: left ventricular ejection fraction (LVEF) ≥ normal low (50%).

6.Women of childbearing age should agree that contraceptive measures (such as intrauterine devices, birth control pills or condoms) must be used within the study period and within 6 months after the end of the study; serum or urine pregnancy test is negative within 7 days prior to enrollment, And must be non-lactating patients; men should agree to patients who have contraceptive use during the study period and six months after the end of the study period.

Exclusion Criteria:

  1. patients who have previously used EGFR-TKI drugs;
  2. small cell lung cancer (including small cell carcinoma and non-small cell carcinoma mixed lung cancer);
  3. central type, with empty lung squamous cell carcinoma, or with non-small cell lung cancer with hemoptysis (> 50 ml / day) 4.5 years or at the same time with other malignancies, cured cervical carcinoma in situ, non-melanoma skin cancer and superficial bladder tumor except [Ta (non-invasive tumor), Tis (carcinoma in situ ) And T1 (tumor infiltrating basement membrane)];

5.Whole-body antitumor therapy was planned within 4 weeks prior to randomization or during the course of this study, including cytotoxic therapy, signal transduction inhibitors, immunotherapy (or use of mitogen at 6 weeks prior to administration of the test drug) C); 6.patients with symptomatic or unstable brain metastases; 7.patients with any severe and / or uncontrolled disease, including: A) cirrhosis, acute or active hepatitis; B) history of immunodeficiency, including HIV-positive or other acquired, congenital immunodeficiency disease, or history of organ transplantation; C) patients with seizures and who need treatment; 8.active or uncontrollable serious infection (≥CTC AE Level 2 infection); 9.with a history of mental illness and can not quit or have mental disorders; 10.participated in other anti-tumor drug clinical trials within four weeks; 11.According to the judge's judgment, there is an impact on the absorption of oral drugs or serious harm to the safety of patients is not suitable for participation in the study of the situation.

Layout table for additonal information
Responsible Party: Jiangsu Famous Medical Technology Co., Ltd.
ClinicalTrials.gov Identifier: NCT03264794    
Other Study ID Numbers: CTTQ-20161017
First Posted: August 29, 2017    Key Record Dates
Last Update Posted: August 29, 2017
Last Verified: January 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Gefitinib
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action